Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women
| Status: | Completed |
|---|---|
| Conditions: | Osteoporosis, Osteoporosis, Postmenopausal Syndrome |
| Therapuetic Areas: | Endocrinology, Rheumatology |
| Healthy: | No |
| Age Range: | 50 - 90 |
| Updated: | 4/21/2016 |
| Start Date: | August 2007 |
| End Date: | July 2008 |
Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.
To develop a decision aid to support the decision to use (or not use) bisphosphonates in
postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the
decision aid on start and six month adherence to bisphosphonates.
postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the
decision aid on start and six month adherence to bisphosphonates.
Bisphosphonates can reduce fracture risk in patients with osteoporosis. However, many
patients may not start and adhere to bisphosphonates, consequently losing independence,
quality, and length of life. We hypothesize that a decision aid that efficiently improves
patient education and communication with their provider about fracture risk, and about using
bisphosphonates to reduce that risk, will improve the quality of treatment decisions. We
anticipate that patients will become more involved in the decision-making process and
decisions will be more consistent with patients' values and health care goals. We expect
this will lead to increased bisphosphonate start and adherence and improved patient
outcomes.
patients may not start and adhere to bisphosphonates, consequently losing independence,
quality, and length of life. We hypothesize that a decision aid that efficiently improves
patient education and communication with their provider about fracture risk, and about using
bisphosphonates to reduce that risk, will improve the quality of treatment decisions. We
anticipate that patients will become more involved in the decision-making process and
decisions will be more consistent with patients' values and health care goals. We expect
this will lead to increased bisphosphonate start and adherence and improved patient
outcomes.
Inclusion Criteria:
- Female, post-menopausal women aged 50 to 90.
- Have a bone mineral density (BMD) evaluation resulting in a T-Score of <-1.0.
- Have a follow-up appointment with a provider in the areas of Family Medicine (FM),
Primary Care Internal Medicine (PCIM), or POM.
- Have no major barriers (i.e., severe hearing impairment, dementia, require
interpreter, etc.) to participation in shared decision-making (per provider's
assessment)
- Enrollment is open to females of diverse racial backgrounds.
Exclusion Criteria:
- Currently taking a bisphosphonate.
- Not available for 6 month follow-up phone call.
We found this trial at
1
site
Click here to add this to my saved trials
